,Canonical_Smiles,drug_name,drug_type,Label
0,C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,Chinin,GST-Inhibitor,negative
1,C=CCC1([C@H](C)CCC)C(=O)NC(=O)NC1=O,Secobarbital,2C9-Inducer,positive
2,C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],Aztreonam,P450_HFLA-Substrate,negative
3,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,Betaxolol,2D6-Substrate,negative
4,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
5,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,2D6-Inhibitor,negative
6,Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1,Bupranolol,2D6-Substrate,negative
7,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,Manidipine,2D6-Inhibitor,negative
8,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,Ketoprofen,GST-Inhibitor,negative
9,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],Dipotassium clorazepate,-,negative
10,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,Tolcapone,Methyltransferase-Inhibitor,negative
11,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
12,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,Dapsone,2C9-Inducer,positive
13,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,Avasimibe,-,negative
14,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,Naproxen,SUL-Inhibitor,negative
15,C#CCN(C)Cc1ccccc1,Pargyline,2E1-Inhibitor,negative
16,[Cl-].[Na+],Sodium Chloride,2E1-Inducer,negative
17,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,Colchicine,2C9-Inducer,positive
18,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
19,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Cholic Acid,SUL-Substrate,negative
20,C=CCOc1ccccc1OC[C@H](O)CNC(C)C,Oxprenolol,2D6-Inhibitor,negative
21,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,Buflomedil,2D6-Substrate,negative
22,CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12,Pindolol,2D6-Substrate,negative
23,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,Prazepam,3A4-Substrate,negative
24,C=CCc1ccc2c(c1)OCO2,safrole,2E1-Substrate,negative
25,c1ccc2[nH]c(-c3cscn3)nc2c1,Tiabendazole,-,negative
26,C[C@@H](CN1c2ccccc2Sc2ccc(S(=O)(=O)N(C)C)cc21)N(C)C,Dimetotiazine,3A4-Inhibitor,negative
27,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
28,CN(C)CCCN1c2ccccc2CCc2ccccc21,Imipramine,CP2CI-Substrate,negative
29,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C,Lacidipine,-,negative
30,FC(F)OC(F)(F)[C@H](F)Cl,Enflurane,2E1-Substrate,negative
31,CC(=O)Nc1ccccc1,Acetanilide,-,negative
32,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Pentoxifylline,GST-Inducer,negative
33,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
34,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
35,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
36,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,Ceftriaxone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
37,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
38,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
39,CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan_carboxaldehyde_EXP_3179,2C9-Substrate,negative
40,O=[P@]1(N(CCCl)CCCl)OCCCN1CCCl,trofosfamide,3A4-Substrate,negative
41,COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC)cc(OC)c3c1OCO3)OCO2,DDB_aka_BDD,2C9-Substrate,negative
42,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C=O)C[C@@H]21,11_oxo_delta_8_tetrahydro_cannabinol,2D6-Substrate,negative
43,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
44,CC(C)[C@H]1CC[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC1,Nateglinide,P450_HFLA-Substrate,negative
45,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,Ivabradine,3A4-Substrate,negative
46,CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1,Efonidipine,-,negative
47,Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,Cefazolin,Solute_carrier_family_22_member_6-Substrate,negative
48,CCc1cccc2c3c([nH]c12)[C@](CC)(CC(=O)O)OCC3,Etodolac,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor,negative
49,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12,Corticosterone,-,negative
50,CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,Aprindine,2D6-Substrate,negative
51,Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,Thiamine (vit B1),P450_HP-Inducer,negative
52,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2E1-Inhibitor,negative
53,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Amprenavir,2D6-Substrate,negative
54,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Acarbose,2E1-Inducer,negative
55,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,Dinoprostone,19A-Inducer,negative
56,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,Paclitaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
57,CCC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Hydroquinidine,-,negative
58,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
59,COC(=O)Nc1nc2cc(Sc3ccccc3)ccc2[nH]1,Fenbendazole,1A2-Inducer,negative
60,c1ccc2c(c1)ccc1ccccc12,phenanthrene,1A2-Substrate,negative
61,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,Azatadine,-,negative
62,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
63,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,Ribavirin,Solute_carrier_family_28_member_3-Substrate,negative
64,C[N+](C)(C)CCOC(N)=O,Carbachol,N_acetyltransferase-Inhibitor,negative
65,C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,Exemestane,19A-Inhibitor,negative
66,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,Cyclobenzaprine,2D6-Substrate,negative
67,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D3,3A4-Substrate,negative
68,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
69,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,Desoxycortone,Steroid_11_beta_hydroxylase-Substrate,negative
70,CN[C@@H](C)Cc1ccccc1OC,Methoxyphenamine,2D6-Substrate,negative
71,Nc1nc2cc(Cl)ccc2o1,Zoxazolamine,-,negative
72,CN1C(=O)[C@H](O)N=C(c2ccccc2)c2cc(Cl)ccc21,Temazepam,-,negative
73,CNC[C@@H](O)c1ccc(O)cc1,Oxedrine,N_acetyltransferase-Inhibitor,negative
74,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Pergolide,2D6-Inhibitor,negative
75,CC(C)[C@H](N)C(=O)OC[C@H](CO)OCn1cnc2c(=O)nc(N)[nH]c21,Valganciclovir,Solute_carrier_family_15_member_2-Inhibitor,negative
76,Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,Folic Acid,2E1-Substrate,negative
77,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
78,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,Etoricoxib,2E1-Inhibitor,negative
79,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,taxol,2C8-Substrate,negative
80,CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,Angiotensinamide,Methyltransferase-Inducer,negative
81,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,Quinapril,Solute_carrier_family_15_member_2-Inhibitor,negative
82,COc1ccc(CCN(C)CCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,Verapamil,GST-Inducer,negative
83,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
84,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,Methotrexate,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
85,CCCCCCCCC,nonane,2E1-Substrate,negative
86,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Simvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
87,COC(=O)c1c(C)nc(C)c(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)c1-c1cccc([N+](=O)[O-])c1,barnidipine_M8,3A4-Substrate,negative
88,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
89,CN1CCN(C2=Nc3cc(F)ccc3Cc3ccccc32)CC1,Fluperlapine,2D6-Substrate,negative
90,COSc1cn(C)c2cc(F)ccc2c1=O,Flosequinan,-,negative
91,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,Amoxicillin,Solute_carrier_family_22_member_6-Substrate,negative
92,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Chenodeoxycholic Acid,GST-Inhibitor,negative
93,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
94,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Pefloxacin,-,negative
95,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,Saquinavir,P450_HFLA-Substrate,negative
96,Cc1ccccc1C(OCCN(C)C)c1ccccc1,Orphenadrine,2D6-Substrate,negative
97,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Quinidine,2E1-Substrate,negative
98,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
99,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,Quazepam,2C19-Substrate,negative
100,NCCc1c[nH]cn1,Histamine,2E1-Inducer,negative
101,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vindesine,-,negative
102,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Dasatinib,UGT-Inhibitor,negative
103,C=C[C@@H](N)CCC(=O)O,Vigabatrin,Proton_coupled_amino_acid_transporter_1-Substrate,negative
104,Nc1nc(OCc2ccccc2)c2nc[nH]c2n1,O6_benzylguanine,1A2-Substrate,negative
105,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=N[C@H]1O,Oxazepam,P450_HFLA-Substrate,negative
106,CCc1ccccc1,Ethylbenzene,-,negative
107,CN(C)CCC=C1c2ccccc2Sc2ccc(Cl)cc21,Chlorprothixene,3A4-Substrate,negative
108,CC(=O)Nc1ccc(O)cc1,Paracetamol,2E1-Inducer,negative
109,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,Pimozide,2E1-Inhibitor,negative
110,CC(C)=C[C@@H]1[C@@H](C(=O)OCN2C(=O)C3=C(CCCC3)C2=O)C1(C)C,Tetramethrin,3A4-Inducer,negative
111,CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,Benzethonium,2D6-Substrate,negative
112,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,Mizolastine,2E1-Inhibitor,negative
113,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,bortezomib,2D6-Substrate,negative
114,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,Clozapine,2E1-Inhibitor,negative
115,CN(C)CCN(Cc1ccccc1)c1ccccn1,Tripelennamine,2D6-Inhibitor,negative
116,CN[C@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,Frovatriptan,-,negative
117,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O,androstenedione,3A4-Substrate,negative
118,CC1O[C@@]2(CS1)CN1CCC2CC1,Cevimeline,2D6-Substrate,negative
119,c1ccccc1,Benzene,-,negative
120,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Methyltestosterone,19A-Inducer,negative
121,CCOP(=S)(OCC)SCSCC,phorate,2C19-Substrate,negative
122,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
123,FC(F)O[C@@H](Cl)C(F)(F)F,Isoflurane,2E1-Substrate,negative
124,CC1=CC[C@H]2[C@@H](C1)C2(C)C,delta_3_carene,2D6-Substrate,negative
125,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,all_trans_retinoic_acid,2C9-Substrate,negative
126,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,Tasosartan,-,negative
127,Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,Tocopherol (vit E),2E1-Inhibitor,negative
128,CC(N)C(=O)c1ccccc1,Cathinone,-,negative
129,O=C(O)CCCC[C@@H]1SC[C@H]2NC(=O)N[C@H]21,Biotin,1B1-Inducer,negative
130,CCN(CC)CCS(=O)(=O)C1CCN2C(=O)c3coc(n3)CC(=O)CC(O)C=C(C)C=CCNC(=O)C=CC(C)C(C(C)C)OC(=O)C12,Dalfopristin,-,negative
131,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
132,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,Pravastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
133,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,Tolbutamide,CP2CI-Substrate,negative
134,OCCc1ccccc1Nc1c(Cl)cccc1Cl,diclofenac_deriv_2,2C19-Substrate,negative
135,CCCCCCCCCCCC(=O)O,lauric_acid,2E1-Substrate,negative
136,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,Zaleplon,P450_HFLA-Substrate,negative
137,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@@H](NC(=N)N)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O,Dihydrostreptomycin,3A4-Substrate,negative
138,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,Trimethoprim,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
139,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,2C9-Inducer,positive
140,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
141,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
142,O=C(O)Cc1cc(O)ccc1Nc1c(Cl)cccc1Cl,5_hydroxy_diclofenac,2C9-Substrate,negative
143,NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,Liothyronine,-,negative
144,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer,negative
145,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,Zotepine,2D6-Substrate,negative
146,Cc1cccc(C)c1,xylene_meta,2E1-Substrate,negative
147,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,Methylprednisolone,-,negative
148,CCCCC[C@H](O)C=C[C@@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,Alprostadil,Multidrug_resistance_associated_protein_4-Substrate,negative
149,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,Retigabine,1A1-Substrate,negative
150,O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,kaempferol,1A2-Substrate,negative
151,C[C@@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,Labetalol,2D6-Inhibitor,negative
152,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC,Etoperidone,2D6-Substrate,negative
153,COc1ccc(OC)c([C@H](O)CNC(=O)CN)c1,Midodrine,2D6-Inhibitor,negative
154,CC(C(=O)c1ccc2c(c1)OCO2)N1CCCC1,MDPPP,2D6-Substrate,negative
155,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
156,C#CCC12CCC(=O)C=C1CCC1C3CCC(=O)C3(C)CCC12,Plomestane,-,negative
157,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,terbinafine,2C19-Substrate,negative
158,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,Desloratadine,2D6-Inhibitor,negative
159,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,Diflunisal,UGT-Substrate,negative
160,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,Budipine,2D6-Inhibitor,negative
161,CC(C)(C)NCC(O)COc1ccccc1C#N,Bunitrolol,2D6-Substrate,negative
162,CCO,Ethanol,4A11-Inducer,negative
163,CN1C(=O)CCC1c1cccnc1,Cotinine,-,negative
164,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,Colecalciferol,2D6-Inhibitor,negative
165,C[C@@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,Flumequine,2E1-Inhibitor,negative
166,CC(=O)N[C@H](CS)C(=O)O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer,negative
167,CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32,Vincamine,2E1-Substrate,negative
168,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1,Mianserin,2D6-Substrate,negative
169,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,Gemfibrozil,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
170,CN[C@@H](C)[C@H](O)c1ccccc1,Ephedrin,SUL-Substrate,negative
171,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,2E1-Inhibitor,negative
172,O=C1C[C@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21,naringenin,1A2-Substrate,negative
173,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1C2=Cc1ccc(Cl)cc1,Lumefantrine,-,negative
174,CCC1(CC)C(=O)NC(=O)N(C)C1=O,Metharbital,1B1-Inducer,negative
175,COc1ccc(CCNCCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_S,2C8-Substrate,negative
176,NNC(=O)c1ccncc1,Isoniazid,2E1-Inducer,negative
177,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
178,O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-],Trospium chloride,-,negative
179,c1ccc(C2(c3ccccc3)C[C@H]2C2=NCCN2)cc1,Cibenzoline,2D6-Substrate,negative
180,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,Chlorpropamide,2C19-Substrate,negative
181,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C,Ciclesonide,3A4-Substrate,negative
182,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,Melatonin,19A-Inhibitor,negative
183,CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,Terguride,2D6-Substrate,negative
184,CCOC(=O)c1ccc(N)cc1,Benzocaine,2E1-Inhibitor,negative
185,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
186,O=C(O)COc1ccc(C(=O)c2cccs2)cc1,suprofen_desmethyl,2C9-Substrate,negative
187,CC(C)(Oc1ccc(Cl)cc1)C(=O)O,Clofibric acid,-,negative
188,CCN(CC)CC(=O)Nc1c(C)cccc1C,Lidocain,CP2CI-Substrate,negative
189,CCOC(=O)C[C@H](SP(=S)(OC)OC)C(=O)OCC,Malathion,-,negative
190,CN1CCC[C@H]1c1cccnc1,Nicotine,2E1-Inducer,negative
191,COc1ccc2ccc(=O)oc2c1,7_methoxy_coumarin,2E1-Substrate,negative
192,ClC(Cl)Cl,Chloroform,2E1-Substrate,negative
193,O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1,Trifluperidol,2D6-Substrate,negative
194,[Hg],"Mercury, Metallic",4A11-Inhibitor,negative
195,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
196,COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate,negative
197,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate,negative
198,COc1c(N2CCN[C@@H](C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Gatifloxacin,-,negative
199,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,halofantrine_R,2C8-Substrate,negative
200,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,Clobazam,CP2CI-Substrate,negative
201,OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O,Inosine,Solute_carrier_family_28_member_3-Inhibitor,negative
202,CCCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(=O)CC,Rokitamycin,-,negative
203,Nc1ccc(C(=O)O)cc1,Aminobenzoic Acid,SUL-Substrate,negative
204,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,Tramadol,2D6-Inhibitor,negative
205,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,Cyproheptadin,UGT-Substrate,negative
206,C[N+](C)(C)C[C@H](O)CC(=O)[O-],Levocarnitine,2E1-Substrate,negative
207,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@H]3SC(=O)NC3=O)cc1)O2,troglitazone,2C8-Substrate,negative
208,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,Cefmetazole,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
209,O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,Rebamipide,-,negative
210,Cc1cc(O)cc(C)c1Cl,Chloroxylenol,2E1-Substrate,negative
211,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](CC)C[C@@]21C,org_4060,3A4-Substrate,negative
212,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,Ivermectin,-,negative
213,CC=CC[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,Ciclosporin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
214,CCCN(CCC)CCc1cccc2c1CC(=O)N2,Ropinirole,2D6-Inhibitor,negative
215,O=C1CN=C(c2ccccc2F)c2cc(Cl)ccc2N1CC(F)(F)F,2_oxo_quazepam,2C9-Substrate,negative
216,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,Etacrynic Acid,GST-Substrate,negative
217,NNCCc1ccccc1,Phenelzine,P450_HFLA-Inhibitor,negative
218,CC(O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Lisofylline,-,negative
219,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,Formoterol,2D6-Substrate,negative
220,O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,Glafenine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,negative
221,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
222,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN[C@H](C)C3)c(F)c21,Lomefloxacin,-,negative
223,C=C(C)C1CO1,isoprene_epoxide_2,2E1-Substrate,negative
224,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1,Tirilazad,-,negative
225,N#Cc1ccc(C2CCCc3cncn32)cc1,Fadrozole,-,negative
226,CCN(CC)CCc1nc(-c2ccccc2)no1,Oxolamine,1B1-Inducer,negative
227,CSCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O,Corticotropin,SUL-Inducer,negative
228,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,-,negative
